The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.
 
Nilofer Saba Azad
Honoraria - AMAG Pharmaceuticals; Bayer/Onyx
Consulting or Advisory Role - AMAG Pharmaceuticals; Dava Oncology
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Intensity Therapeutics; Merck (Inst); Syndax (Inst)
 
Keisuke Shirai
Consulting or Advisory Role - Takeda
 
Autumn Jackson McRee
Research Funding - Inovio Pharmaceuticals (Inst); Merck (Inst); Merck (Inst); Novartis (Inst)
 
Mateusz Opyrchal
Consulting or Advisory Role - AstraZeneca
Research Funding - Pfizer
 
Douglas Buckner Johnson
Consulting or Advisory Role - Array Biopharma; Bristol-Myers Squibb; Genoptix; Incyte; Merck; Novartis
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
 
Peter Ordentlich
Employment - Syndax
Leadership - Syndax
Stock and Other Ownership Interests - Syndax
 
Susan Brouwer
Employment - Syndax
Stock and Other Ownership Interests - Syndax
 
Serap Sankoh
Employment - Syndax
Stock and Other Ownership Interests - Syndax
 
Emmett V. Schmidt
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Michael L. Meyers
Employment - Syndax
Leadership - Syndax
Stock and Other Ownership Interests - Syndax
 
Melissa Lynne Johnson
Consulting or Advisory Role - Astellas Pharma (I); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Genentech/Roche (Inst); Otsuka (I)
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Genmab (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Stem CentRx (Inst); Tarveda Therapeutics (Inst)